Moderna (NASDAQ:MRNA) Releases Earnings Results, Beats Estimates By $0.06 EPS

Moderna (NASDAQ:MRNA) posted its quarterly earnings results on Friday. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06, FiscalAI reports. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the firm earned ($2.13) earnings per share. Moderna’s quarterly revenue was up 2.1% on a year-over-year basis.

Here are the key takeaways from Moderna’s conference call:

• 2026 revenue and cost outlook improved: Moderna reiterated revenue growth of up to 10% and lowered its full-year cost-of-sales and R&D forecasts by $100 million each, while reducing expected cash costs by $200 million to approximately $4 billion.
• Flu vaccine advances toward potential approval: mRNA-1010 received a unanimous positive recommendation from the FDA advisory committee, with a U.S. PDUFA decision expected August 5 and regulatory reviews ongoing in Europe, Canada, and Australia.
• mNEXSPIKE showed strong initial commercial traction: The COVID vaccine captured approximately 24% of the U.S. retail market in its first season and about 34% among adults aged 65 and older, supported by encouraging real-world effectiveness data against hospitalization.
• Norovirus vaccine development faces a delay: mRNA-1403 did not meet statistical criteria for early success at its interim analysis, requiring enrollment of an additional cohort and another seasonal period to collect sufficient cases; the trial remains blinded.
• Pipeline milestones remain active: Moderna expects an interim analysis for the fully enrolled phase III intismeran melanoma study in the second half of 2026 and data from its registrational propionic acidemia study in the fourth quarter, while expanding oncology programs into Lynch syndrome and solid tumors.

Moderna Stock Performance

Shares of MRNA stock opened at $54.82 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $85.60. The stock’s 50-day moving average is $59.37 and its two-hundred day moving average is $52.51. The firm has a market cap of $21.75 billion, a P/E ratio of -6.73 and a beta of 0.94.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on MRNA shares. Royal Bank Of Canada upped their target price on Moderna from $38.00 to $45.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Wolfe Research restated an “underperform” rating and set a $25.00 price target on shares of Moderna in a report on Monday, July 20th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, June 18th. Piper Sandler upped their price objective on shares of Moderna from $69.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, June 26th. Finally, UBS Group reiterated a “neutral” rating on shares of Moderna in a research report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Reduce” and a consensus target price of $40.00.

Insider Activity

In related news, President Stephen Hoge sold 53,336 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider directly owned 67,468 shares in the company, valued at approximately $3,373,400. The trade was a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 119,406 shares of company stock worth $5,928,762 in the last three months. 10.80% of the stock is owned by insiders.

Institutional Trading of Moderna

Several large investors have recently added to or reduced their stakes in the business. Invesco Ltd. raised its holdings in shares of Moderna by 15.7% during the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after purchasing an additional 1,115,131 shares in the last quarter. Theleme Partners LLP raised its holdings in Moderna by 8.6% during the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock valued at $217,100,000 after buying an additional 626,420 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Moderna by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock worth $136,290,000 after buying an additional 309,126 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Moderna during the 4th quarter valued at about $95,209,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Moderna by 123.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,788,951 shares of the company’s stock valued at $52,775,000 after acquiring an additional 987,312 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported second-quarter EPS of -$1.97, better than the roughly -$2.03 consensus and an improvement from -$2.13 a year earlier. Revenue was approximately $145 million, while management reiterated its plan for up to 10% revenue growth in 2026. Moderna Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: The company improved its 2026 operating-expense outlook by about $200 million and now expects year-end cash of $4.7 billion to $5.2 billion, supporting its effort to reduce cash burn. Moderna also faces a potentially important catalyst on August 5, when regulators are scheduled to decide on its seasonal flu vaccine candidate, mFLUSIVA. Moderna Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Trading activity showed elevated interest in Moderna call options, with 82,913 contracts acquired versus a typical daily volume of 48,590. This may indicate speculative bullish positioning, but options activity alone does not establish a sustained change in investor sentiment.
• Negative Sentiment: Moderna’s Phase 3 mRNA-1403 norovirus vaccine trial did not meet the statistical criteria for early success at its interim analysis. The company plans to add another participant cohort, extending the trial into a fourth season and delaying clarity on a potential commercial opportunity. Moderna Adds New Cohort to Phase III Vaccine Trial
• Negative Sentiment: Investors remain concerned about Moderna’s dependence on declining COVID-19 vaccine sales. Although the quarterly loss narrowed, the company still posted a GAAP net loss of about $782 million, and reports characterized revenue as weaker than Wall Street expected. The norovirus setback therefore outweighed the earnings and cost-control improvements. Moderna Misses Quarterly Revenue Estimates on COVID Vaccine Weakness

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.